COMP <GO>
CR vs TMO // 10Y YIELD & FRED MACRO BETA
Crane Company (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CR 12
— TMO 3
▲ 10Y YIELD & FRED MACRO BETA LEADER: CR
LAST: $198.02 (-3.79%) • MKT CAP: $11.90B
macro-sensitivity
1.09
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
macro-sensitivity
0.94
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CR VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CR | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 42.20% | 41.00% | +1.20 | CR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.40% | 9.30% | +3.10 | CR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | 30.4x | -5.90 | CR | /valuation <GO> |
| Free Cash Flow Yield | 2.64% | 2.40% | +0.24 | CR | /fcf-yield <GO> |
| Operating Margin | 18.40% | 17.40% | +1.00 | CR | /operating-margins <GO> |
| Net Profit Margin | 15.90% | 15.10% | +0.80 | CR | /net-margins <GO> |
| Revenue Growth (YoY) | 8.20% | 3.90% | +4.30 | CR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.24% | +0.20 | CR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.16 | 4.50 | +1.66 | CR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | CR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.70% | +0.50 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.4 | 59.1 | -11.73 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.09 | 0.94 | +0.15 | CR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.1x | 36.3x | -6.20 | CR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.90B | $262.22B | -$250.32B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CR REV | TMO REV | CR GROSS % | TMO GROSS % | CR FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.31B | $44.56B | 42.2% | 44.0% | $306.9M | $6.29B |
| FY 2024 | $2.13B | $42.88B | 40.7% | 44.0% | $234.2M | $7.27B |
| FY 2023 | $1.86B | $42.86B | 44.0% | 44.0% | $202.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CR // BETA 1.09
TMO // BETA 0.94